MiMedx not aware of any investigation by the Dept. of Justice
MiMedx Group stated "The company is not aware of any investigation of MiMedx by the Department of Justice. In fact, three years ago a competitor filed a qui tam suit against the company, and the DoJ declined to intervene, resulting in a dismissal of the case. As the company announced last week, the audit committee of the company's board of Directors and its independent advisers are investigating certain sales and distribution activities, which it expects will be completed in as timely a manner as possible. The company is confident this course of action is in the best long-term interests of the company and its shareholders. The public should be well aware that the company has been under a concerted, illegal short selling attack since September. This group of illegal short sellers, which the company believes includes Marc Cohodes, Aurelius Value, Viceroy Research, and other numerous hedge funds and individuals, has publicized a continuous stream of misinformation and lies about numerous aspects of the company's business... The situation is complicated by the fact that the company has terminated certain employees for cause over the last 15 months. The company believes certain of these employees are retaliating by acting in concert with this group of short sellers to distort information and negatively impact the company's stock price. In response to a specific allegation in a recent Bloomberg article that the company has charged higher prices to federal accounts than commercial accounts, the company denies that it has engaged in such practice. The other allegations that have been made by this illegal short selling cabal have been answered quite effectively on the MiMedx website under "Short Selling Commentary"... In addition, MiMedx reaffirmed that, based on information available to date, the independent investigation by its audit committee and their legal and accounting advisors should not have a material impact on the company's 2018 revenue guidance of $383M-$387M."